Estimated dispatch within 24 working hours.
ONLY 98p with Regular Delivery
Indicated for the treatment of clinical signs associated with Equine Cushing’s Disease. Prescription Required.
Pink, rectangular scored tablet, engraved on one side with the Boehringer Ingelheim logo and the letters “PRD”. The tablets can be divided into equal halves. Each tablet contains 1.0 mg pergolide (as pergolide mesylate 1.31 mg).
Symptomatic treatment of clinical signs associated with Pituitary Pars Intermedia Dysfunction, PPID (Equine Cushing’s Disease).
The product should be administered orally, once daily. To facilitate administration, the required daily dose should be placed in a small amount of water and/or mixed with molasses or other sweetener and agitated until dissolved. In this case, the dissolved tablets should be administered with a syringe. The whole amount should be administered immediately. Tablets should not be crushed.
The starting dose is 2 µg pergolide/kg body weight. Studies from the published literature cite the most common, average dose as 2 µg pergolide/kg with a range from 0.6 – 10 µg pergolide/kg (0.25 mg – 5 mg total daily dose per horse). The starting dose (2 µg pergolide/kg) should then be titrated according to the individual response as determined by monitoring (see below). Starting doses are recommended as follows:
Horse Body Weight
Number of Tablets
200 - 400 kg
1.3 - 2.5 μg/kg
400 - 600 kg
1.7 - 2.5 μg/kg
601 - 850 kg
1.8 - 2.5 μg/kg
851 - 1000 kg
2.0 - 2.4 μg/kg
Life long treatment is anticipated for this disease. Most horses respond to therapy and are stabilised at an average dose of 2 µg pergolide/kg body weight. Clinical improvement with pergolide is expected within 6 to 12 weeks. Horses may respond clinically at lower or varying doses; it is therefore recommended to titrate to the lowest effective dose per individual based on response to therapy, whether it is effectiveness or signs of intolerance. Some horses may require doses as high as 10 µg pergolide/kg body weight per day. In these rare situations, appropriate additional monitoring is advised.
Following initial diagnosis, repeat endocrinologic testing for dose titration and monitoring of treatment at intervals of 4 to 6 weeks until stabilisation or improvement of clinical signs and/or diagnostic testing occurs. Clinical signs are: hirsutism, polyuria, polydipsia, muscle wasting, abnormal fat distribution, chronic infections, laminitis, sweating, etc. The approach to treatment is the dose titration to the lowest effective dose per individual, based on response to therapy, whether it is effectiveness or signs of intolerance. Depending on the severity of the disease, time to treatment response may vary among individuals. If clinical signs or the diagnostic testing have not yet improved at the first 4 to 6 week interval, the total daily dose may be increased by 0.5 mg. In case clinical signs have improved but are not yet normalised, the veterinarian may decide to titrate or not to titrate the dose, considering the individual’s response/tolerance to the dose. In case clinical signs are not adequately controlled (clinical evaluation and/or diagnostic testing) it is recommended to increase the total daily dose by 0.5 mg increments every 4 to 6 weeks until stabilisation occurs and if the drug is tolerated at that dose. If signs of dose intolerance develop, treatment should be stopped for 2-3 days and reinstated at one-half of the previous dose. The total daily dose may then be titrated back up to the desired clinical effect by 0.5 mg increments every 2-4 weeks. If a dose is missed, the next scheduled dose should be administered as prescribed. Following stabilisation, regular clinical assessment and diagnostic testing should be performed every 6 months to monitor treatment and dose. Where there is no apparent response to treatment, the diagnosis should be re-evaluated.
Do not use in horses with hypersensitivity to pergolide mesylate or other ergot derivatives.
Do not use in horses less than 2 years of age.
Appropriate endocrinologic laboratory tests should be conducted as well as evaluation of clinical signs in order to establish a diagnosis of PPID. As the majority of cases of PPID are diagnosed in aged horses, other pathological processes are frequently present. Potential adverse reactions in horses include inappetence, transient anorexia and lethargy, mild central nervous system signs (e.g. mild depression and mild ataxia), diarrhoea and colic. If signs of dose intolerance develop, treatment should be stopped for 2-3 days and reinstated at one-half of the previous dose. The total daily dose may then be titrated back up to the desired clinical effect by 0.5 mg increments every 2-4 weeks.
Use with caution if the product is co-administered with other drugs known to affect protein binding. Do not administer concurrently with dopamine antagonists, such as neuroleptics (phenothiazines), domperidone, or metoclopramide, as these agents may reduce the effectiveness of pergolide. There is no clinical experience with massive overdose.
Pregnancy: use only according to the benefit/ risk assessment by the responsible veterinarian. The safety has not been demonstrated in pregnant mares. Laboratory studies in mice and rabbits have not produced any evidence of teratogenic effects. Reduced fertility was seen in mice at a dose of 5.6 mg/kg body weight per day.
Lactation: the use is not recommended in lactating horses, in which the safety of this product has not been demonstrated. In mice, reduced body weights and survival rates in the progeny were attributed to the pharmacological inhibition of prolactin secretion resulting in lactation failure.
Not authorised for use in horses intended for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation. Not authorised for use in mares producing milk for human consumption.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. People with known hypersensitivity to pergolide or other ergot derivatives should avoid contact with the veterinary medicinal product and should not administer it. Splitting or crushing pergolide tablets may cause eye irritation, an irritating smell, or headache. Minimise exposure risks when splitting tablets. Tablets should not be crushed. In case of contact with skin, wash exposed skin with water. In the event of pergolide exposure to the eye, flush the affected eye immediately with water and get medical advice. For nasal irritation, move to fresh air and seek for medical attention if breathing difficulty develops. Pregnant or lactating women should wear gloves when administering the product.
Any unused product or waste materials should be disposed of in accordance with local requirements. For animal treatment only. Keep out of reach and sight of children. Do not store above 25°C. Store the blister in the original carton.
Package sizes: 60, 100 or 160 tablets. Not all pack sizes may be marketed.
Pergolide is a synthetic ergot derivative and is a potent, long-acting dopamine receptor agonist. Both in vitro and in vivo pharmacological studies have demonstrated the activity of pergolide as a selective dopamine agonist with little or no effect on norepinephrine, epinephrine or serotonin pathways at therapeutic doses. As with other dopamine agonists, pergolide inhibits the release of prolactin. In horses with Pituitary Pars Intermedia Dysfunction (PPID) pergolide is believed to exert its therapeutic effect by stimulating dopamine receptors. Further, in horses with PPID, pergolide has been shown to decrease the plasma levels of ACTH, MSH and other pro-opiomelanocortin peptides.
Available pharmacokinetic information in the horse is limited to two small studies using oral doses of doses of 2 µg/kg and 10 µg/kg. These studies demonstrated that pergolide is rapidly absorbed with a short time to peak concentration.
Peak concentrations (Cmax) following an exaggerated dose of 10 µg/kg were low and variable with a mean of ~ 4 ng/mL and a mean terminal half life (T1/2) of ~ 6 hours. The median time of peak concentration (Tmax) was ~0.4 hrs and the area under the curve (AUC) was ~ 14 ng*h/ml. The terminal half life in this study was much shorter than reported in humans. This is likely due to the sensitivity of the analytical assay in this study which did not allow for complete elucidation of the concentration - time profile. Therefore the rapid estimated rate of elimination in this study may not be a true reflection of the elimination phase.
In a second study using a more sensitive analytical assay, plasma concentrations following the use dose of 2 µg/kg were very low and variable with peak concentrations ranging from 138 to 551 pg/ml. The peak concentrations occurred at 1.25 +/- 0.5 hr (Tmax). Plasma concentrations from most horses were quantifiable for only 6 hours post dose. However, one horse had quantifiable concentrations through 24 hours. Terminal half-lives were not calculated as there was incomplete elucidation of the plasma concentration-time curve for most horses. Pergolide mesylate is approximately 90 % associated with plasma proteins in humans and laboratory animals.
Prascend 1mg tablets for horses - 60 tablets
Prascend 1mg tablets for horses - 160 tablets
All prices include VAT where applicable.
There are currently no questions for Prascend for Horses - be the first to ask one!Ask A Question
Sorry that this product is out of stock, instead of having to keep checking back to see if we have it, we can send you a notification as soon as it comes back in stock.
We won't use any details you enter for any other purpose than letting you know when this is back in stock.
Please enter details for each method you'd like us to notify you by:
VetMedsPoints are a way for us to say thank you for purchasing from VetMedsDirect.
You will receive VetMedsPoints by purchasing this product, which can be redeemed for a discount on future purchases. For each 1000 points redeemed at the checkout, you will receive a 20p discount.
The number of VetMedsPoints is shown on the product listing and they are awarded on dispatch of the order.
Terms and conditions apply.